Last edition
News about Global Pharma
Asston Pharmaceuticals Secures International Supply Order Worth INR 2.65 Crore
Asston Pharmaceuticals has received an order from a leading international pharmaceutical company to supply a range of pharma products worth INR 2.65 crore
Global Pharma | 02/09/2025 | By Dineshwori | 278
Four Drugs in Race for First Bispecific ADC Approval: GlobalData
With 21 global approvals, ADCs generated USD 13.6 billion in 2024. BsADCs represent further opportunities in this field, by leveraging bi-specific antibodies that simultaneously bind two distinct targets.
Global Pharma | 02/09/2025 | By Dineshwori | 419
Accro Bioscience and Fosun Pharma Enter Licensing Deal for AC-201 in Greater China
Accro Bioscience has granted Fosun Pharma exclusive rights to develop, manufacture, and commercialise AC-201 — its independently developed, highly selective TYK2/JAK1 inhibitor — in Greater China (including the Chinese Mainland, Hong Kong SAR, and Macau SAR).
Global Pharma | 01/09/2025 | By Dineshwori | 433
Bausch Health Expands Dermatology Portfolio with YUN Probiotherapy Launch in Poland
Following its partnership with Belgian biotech company YUN NV last June, Bausch Health has launched the YUN ACN skincare line in Poland, expanding its dermatology portfolio.
Global Pharma | 01/09/2025 | By Dineshwori | 785
FDA Approves Eisai and Biogen's At-Home Alzheimer's Injection Leqembi IQLIK
Leqembi IQLIK, delivering a 360 mg dose within 15 seconds, will be available from 6 October, 2025, at a list price of USD 19,500 annually for a pack of pre-filled autoinjectors.
Global Pharma | 30/08/2025 | By Dineshwori | 761
Foresee Pharmaceuticals has received US FDA approval for CAMCEVI ETM (21 mg) as a treatment for advanced prostate cancer.
Global Pharma | 30/08/2025 | By Mrinmoy Dey | 573
US FDA Clears Sanofi's Wayrilz, First BTK Inhibitor for ITP
The US FDA approval was based on the pivotal LUNA 3 phase-III study, in which Sanofi’s Wayrilz met the primary and secondary endpoints, showing a positive impact on sustained platelet counts and other ITP symptoms.
Global Pharma | 30/08/2025 | By Dineshwori | 389
Teva Pharmaceuticals Launches First Generic Version of Saxenda in US
The first generic version of Saxenda, Liraglutide injection, is approved for adults with obesity or overweight who have weight-related medical conditions, as well as for paediatric patients aged 12 to 17 years weighing more than 60 kg with obesity.
Global Pharma | 30/08/2025 | By Dineshwori | 935
OPTEL Acquires Vanguard Robotics to Accelerate Innovation in Pharma Automation
OPTEL Group has acquired Vanguard Robotics to strengthen its pharmaceutical automation portfolio with advanced end-of-line cobot solutions.
Global Pharma | 29/08/2025 | By Mrinmoy Dey | 366
Celaid Therapeutics and AGC Ink Research Pact on iPSC-HSPC Expansion and Evaluation
Celaid Therapeutics has partnered with AGC Inc. to advance scalable expansion of iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs) by combining their respective stem cell technologies.
Global Pharma | 29/08/2025 | By Mrinmoy Dey | 141
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy